Literature DB >> 2904735

Antigenic properties of vaccinia virus and of the virus recombinant strains expressing heterologous genes.

N V Chelyapov1, T P Antonova, N N Yanova, V I Chernos.   

Abstract

Immunologic properties of vaccinia virus (VV), strain LIPV, and VV recombinant strains containing the gene of hepatitis B virus surface antigen and the TK gene of herpes simplex virus (HSV) have been studied. Production of antibodies against the majority of VV structural proteins, including nucleocapsid internal proteins was demonstrated in rabbits. Insertion of heterologous genes into the VV genome was without effect on the spectrum of antibodies produced against VV virion proteins. The data obtained in volunteers indicate that not only virus-neutralizing antibodies but also antibodies against most VV structural proteins are preserved in humans over many years. Reimmunization of volunteers with VV recombinant stimulates synthesis of antibodies against virion proteins whereas the spectrum of antibodies remains unchanged. Humans and rabbits did not differ in the spectrum of antibodies to VV virion proteins.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2904735

Source DB:  PubMed          Journal:  Acta Virol        ISSN: 0001-723X            Impact factor:   1.162


  3 in total

1.  Hepatitis B virus proteins expressed by recombinant vaccinia viruses: influence of preS2 sequence on expression surface and nucleocapsid proteins in human diploid cells.

Authors:  L Kutinová; S Nĕmecková; E Hamsíková; H Závadová; V Ludvíková; J Broucek; D Kunke; J König; L G Zakharova; G V Pashvykina
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

2.  A recombinant vaccinia virus expressing hepatitis B virus middle surface protein. Restricted expression of HBV antigens in human diploid cells.

Authors:  L Kutinová; S Nĕmecková; E Hamsíková; M Press; H Závadová; I Hirsch; V Nĕmecek; V Krchnák; J Smrt; D Slonim
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

Review 3.  Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target.

Authors:  A P Zbar; N R Lemoine; M Wadhwa; H Thomas; D Snary; W A Kmiot
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.